Frede Donskov
0000-0002-8449-863X
Publication & Citation Trends
Publications
0 total
Outcomes of complete responders from first-line therapy in metastatic renal cell carcinoma in the real world: an analysis from the International Metastatic Renal Cell Carcinoma Database Consortium
Cited by 0
Semantic Scholar
Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)
Cited by 0
Semantic Scholar
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cited by 1
Semantic Scholar
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Cited by 2
Semantic Scholar
Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.
Cited by 0
Semantic Scholar
2629P Durability of Complete Response (CR) to first-line (1L) in metastatic renal cell carcinoma (mRCC) in the real world
Cited by 0
Semantic Scholar
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol
Cited by 2
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(303)
Cancer Genomics and Diagnostics
(138)
Renal and related cancers
(128)
Cancer Immunotherapy and Biomarkers
(74)
Economic and Financial Impacts of Cancer
(58)
Affiliations
Ontario Institute for Cancer Research
Memorial Sloan Kettering Cancer Center
University of Southern Denmark
Aarhus University
Université Paris-Saclay